Epstein-Barr virus gp350 neutralizing epitopes define distinct sites of vulnerability
Cell Reports · 2026-10 · 45 (10) · 118072
DOI: 10.1016/j.celrep.2026.118072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026-10. Verfasst von Ge-Xin Zhao und 18 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carc…. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Antibodies, Neutralizing, Epitopes. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, National Science and Technology Major Project.
Abstract (Originalsprache)
Epstein-Barr virus (EBV) is a widespread human herpesvirus linked to several malignancies, yet no vaccine has been approved. Its major surface glycoprotein, gp350, mediates attachment to B cells via CR2 binding, but gp350-based vaccines have shown limited protection, raising questions about its neutralizing epitopes and mechanisms. Here, we isolated human monoclonal antibodies from a phage-display library derived from EBV-seropositive donors. Several antibodies showed potent neutralization, including 1A12, which conferred robust protection in a humanized mouse model by markedly reducing viral load and disease pathology. Epitope mapping and structural analysis revealed three distinct antigenic clusters on gp350, including a neutralizing epitope in the distal D3 domain recognized by 1H5, which neutralizes EBV via a post-attachment mechanism. These findings define vulnerable sites on gp350 and offer structural and mechanistic insights for developing next-generation EBV vaccines and antibody-based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Gua…
- State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
- Department of Obstetrics and Gynecology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- National Science and Technology Major Project
- National Key Research and Development Program of China
- Sun Yat-sen University Cancer Center
Zitieren
APA
Zhao, G. X., Li, P. L., Yuan, B. Y., Luo, Q. H., Li, T., Ma, H. Y., Huang, R. J., Bu, G. L., Xie, C., Wu, P. H., Zhou, H., Du, W. T., Wang, J., Fang, D. J., Zeng, M. S., Dong, H. H., Feng, G. K., Zhong, Q., & Sun, C. (2026). Epstein-Barr virus gp350 neutralizing epitopes define distinct sites of vulnerability. Cell Reports, 45(10), 118072. https://doi.org/10.1016/j.celrep.2026.118072
Vancouver
Zhao GX, Li PL, Yuan BY, Luo QH, Li T, Ma HY, et al. Epstein-Barr virus gp350 neutralizing epitopes define distinct sites of vulnerability. Cell Reports. 2026;45(10):118072. doi:10.1016/j.celrep.2026.118072
BibTeX
@article{Zhao2026,
author = {Zhao, Ge-Xin and Li, Peng-Lin and Yuan, Bo-Yu and Luo, Qing-Hua and Li, Ting and Ma, Hai-Yun and Huang, Rui-Juan and Bu, Guo-Long and Xie, Chu and Wu, Pei-Huang and Zhou, Hang and Du, Wen-Ting and Wang, Jing and Fang, Da-Jun and Zeng, Mu-Sheng and Dong, Hao-Hao and Feng, Guo-Kai and Zhong, Qian and Sun, Cong},
title = {Epstein-Barr virus gp350 neutralizing epitopes define distinct sites of vulnerability},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {10},
pages = {118072},
doi = {10.1016/j.celrep.2026.118072}
}
EUVIMED